Sell Erlotinib HCL(CAS:183319-69-9)

CAS: 183319-69-9

Appearance    Almost white to pale yellow powder     Pale yellow powder

Melting Point 228C-230C     228C-230C

Loss on Drying     NMT0.5%      0.3%

Related Impurity by HPLC    

Total impurity  NMT1.5%  0.7%

Single impurity NMT0.3%     0.25%

Assay (HPLC)       NLT99.0%      99.3%

In-house standard

Packing:1kg/tin or according to customer request

U.S. FDA approval of its role standard in the treatment of advanced NSCLC invalid the second-tier or third-line treatment. The results showed that part of the programme combined with chemotherapy did not increase the response rate and survival of patients, for head and neck cancer, metastatic renal cell carcinoma, pancreatic cancer, breast cancer, Tarceva with chemotherapy or other targeted therapy drugs such as Avastin and used to good effect show